EA034135B9 - Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов - Google Patents

Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов

Info

Publication number
EA034135B9
EA034135B9 EA201591598A EA201591598A EA034135B9 EA 034135 B9 EA034135 B9 EA 034135B9 EA 201591598 A EA201591598 A EA 201591598A EA 201591598 A EA201591598 A EA 201591598A EA 034135 B9 EA034135 B9 EA 034135B9
Authority
EA
Eurasian Patent Office
Prior art keywords
pyreceptor
agonists
pharmaceutical compositions
nucleoside derivatives
compositions based
Prior art date
Application number
EA201591598A
Other languages
English (en)
Other versions
EA201591598A1 (ru
EA034135B1 (ru
Inventor
Филип Дж. Хейдон
Цзиньбо Ли
Original Assignee
Тафтс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тафтс Юниверсити filed Critical Тафтс Юниверсити
Publication of EA201591598A1 publication Critical patent/EA201591598A1/ru
Publication of EA034135B1 publication Critical patent/EA034135B1/ru
Publication of EA034135B9 publication Critical patent/EA034135B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к фармацевтическим композициям, содержащим производные уридиновых нуклеозидов формулы I, где значения радикалов такие, как указано в описании изобретения, и к способам использования этих композиций в лечение нарушений, которые чувствительны к лигандам, таким как агонисты рецептора PY, например нейрональных нарушений, включая нейродегенеративные нарушения (например, болезнь Альцгеймера, болезнь Паркинсона) и воспалительные состояния.
EA201591598A 2013-03-13 2014-03-13 Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов EA034135B9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780219P 2013-03-13 2013-03-13
US201361883604P 2013-09-27 2013-09-27
PCT/US2014/026865 WO2014160502A1 (en) 2013-03-13 2014-03-13 Uridine nucleoside derivatives, compositions and methods of use

Publications (3)

Publication Number Publication Date
EA201591598A1 EA201591598A1 (ru) 2016-03-31
EA034135B1 EA034135B1 (ru) 2020-01-09
EA034135B9 true EA034135B9 (ru) 2020-04-10

Family

ID=51625444

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591598A EA034135B9 (ru) 2013-03-13 2014-03-13 Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов

Country Status (19)

Country Link
US (3) US10544183B2 (ru)
EP (2) EP3449925B1 (ru)
JP (1) JP6591957B2 (ru)
KR (1) KR102304242B1 (ru)
CN (1) CN105407898B (ru)
AU (1) AU2014243707B2 (ru)
CA (1) CA2904180C (ru)
DK (1) DK2968385T3 (ru)
EA (1) EA034135B9 (ru)
ES (1) ES2684368T3 (ru)
HK (1) HK1220388A1 (ru)
HU (1) HUE039871T2 (ru)
IL (1) IL241172B (ru)
PL (1) PL2968385T3 (ru)
PT (1) PT2968385T (ru)
SI (1) SI2968385T1 (ru)
TW (1) TWI640533B (ru)
WO (1) WO2014160502A1 (ru)
ZA (1) ZA201507045B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012315671B2 (en) 2011-09-30 2017-07-20 Tufts University Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders
AU2013323188B2 (en) 2012-09-28 2018-04-19 Tufts University Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
DK2968385T3 (en) 2013-03-13 2018-09-03 Univ Tufts URIDINNUCLEOSIDE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR USING THEREOF
US10138265B2 (en) 2013-03-13 2018-11-27 Tufts University Uridine nucleoside derivatives, compositions and methods of use
MX2018012655A (es) 2016-04-21 2019-09-06 Astrocyte Pharmaceuticals Inc Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
JP7311855B2 (ja) 2018-02-09 2023-07-20 アストロサイト ファーマシューティカルズ， インコーポレイテッド 嗜癖および関連する障害を処置するための化合物および方法
KR20210093864A (ko) 2018-09-26 2021-07-28 아스트로사이트 파마슈티컬스, 인코포레이티드 다형성 화합물 및 이의 용도
WO2021026337A1 (en) * 2019-08-07 2021-02-11 Icahn School Of Medicine At Mount Sinai Method of treating keloids
CN116437930A (zh) * 2020-10-30 2023-07-14 上海岸阔医药科技有限公司 尿苷衍生物在制备药物中的应用
WO2022266027A1 (en) * 2021-06-15 2022-12-22 Steven Baranowitz Prevention and treatment of post-infection neurological disorders and clotting/thrombotic disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049686A1 (en) * 2011-09-30 2013-04-04 Tufts University Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0621073B2 (ja) 1986-03-06 1994-03-23 日水製薬株式会社 中枢抑制剤
JP3032053B2 (ja) 1991-09-06 2000-04-10 日水製薬株式会社 ウリジン誘導体及びこれを含有する医薬
US5962459A (en) 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
US6143279A (en) * 1997-08-29 2000-11-07 The University Of North Carolina At Chapel Hill Uridine 5'-diphosphate and analogs useful for treating lung diseases
US8518882B2 (en) 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
ES2476940T3 (es) 1998-07-31 2014-07-15 Massachusetts Institute Of Technology Uso de uridina en combinación con colina para el tratamiento de trastornos emocionales y del humor
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US20060069061A1 (en) 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
US20050203053A1 (en) 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US8314064B2 (en) 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US20070004670A1 (en) 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CA2444161A1 (en) 2003-10-01 2005-04-01 Japan Health Sciences Foundation A screening method of drug for treatment of neuropathic pain
EP1765075A4 (en) 2004-06-10 2010-11-10 Mclean Hospital Corp PYRIMIDINES, IN PARTICULAR URIDINE, USED IN TREATMENTS ON PATIENTS WITH BIPOLAR DISORDERS
CA2579851C (en) * 2004-09-15 2018-09-04 Massachusetts Institute Of Technology Use of uridine for improving cognitive and neurological functions
CN101237772A (zh) * 2005-06-29 2008-08-06 印斯拜尔药品股份有限公司 用于治疗肺病的p2y6受体激动剂
US7851456B2 (en) 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
CN101765369A (zh) 2007-03-19 2010-06-30 俄勒冈州由俄勒冈州立大学代表州高等教育委员会行使 曼尼希碱n-氧化物药物
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2737661C (en) 2008-09-23 2019-08-20 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
IT1398378B1 (it) 2010-02-22 2013-02-22 Omikron Italia S R L Citicolina per il trattamento del glaucoma e dell'ipertensione oculare.
CN103339136A (zh) * 2010-12-01 2013-10-02 巴伊兰大学 尿苷二-或三-磷酸衍生物以及其用途
AU2013323188B2 (en) 2012-09-28 2018-04-19 Tufts University Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
US10138265B2 (en) 2013-03-13 2018-11-27 Tufts University Uridine nucleoside derivatives, compositions and methods of use
DK2968385T3 (en) * 2013-03-13 2018-09-03 Univ Tufts URIDINNUCLEOSIDE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR USING THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049686A1 (en) * 2011-09-30 2013-04-04 Tufts University Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BANERJEE, D. et al., "Efficient and Convenient Palladium-Catalyzed Amination of Allylic Alcohols with N-Heterocycles", Angewandte Chemie International Edition (2012), Vol. 51, No. 46, pages 11556-11560, see compound 3r, scheme 3 *
CAS RN 106362-71-4 *
CAS RN 110104-24-0 *
CAS RN 114766-52-8 *
CAS RN 129141-73-7 *
CAS RN 166190-75-6 *
CAS RN 166190-76-7 *
CAS RN 50908-28-6 *
CAS RN 51172-66-8 *
KIMURA, T. et al., "Metabolism of a novel hypnotic, N3-phenacyluridine, and hypnotic and sedative activities of its enantiomer metabolites in mouse", Xenobiotica (2000), Vol. 30, No. 6, pages 643-653, see Abstract section 6; table 2; figure 6 *

Also Published As

Publication number Publication date
JP6591957B2 (ja) 2019-10-16
US10544183B2 (en) 2020-01-28
TWI640533B (zh) 2018-11-11
DK2968385T3 (en) 2018-09-03
US20200399302A1 (en) 2020-12-24
CA2904180C (en) 2022-05-10
EP2968385B1 (en) 2018-05-23
NZ712391A (en) 2020-12-18
WO2014160502A1 (en) 2014-10-02
AU2014243707B2 (en) 2018-08-30
HUE039871T2 (hu) 2019-02-28
TW201444860A (zh) 2014-12-01
KR102304242B1 (ko) 2021-09-17
HK1220388A1 (zh) 2017-05-05
EP3449925B1 (en) 2021-08-04
CN105407898A (zh) 2016-03-16
EP2968385A4 (en) 2016-08-10
CN105407898B (zh) 2021-06-15
AU2014243707A1 (en) 2015-10-08
US20220135611A1 (en) 2022-05-05
IL241172B (en) 2019-07-31
EA201591598A1 (ru) 2016-03-31
IL241172A0 (en) 2015-11-30
ES2684368T3 (es) 2018-10-02
CA2904180A1 (en) 2014-10-02
EP3449925A1 (en) 2019-03-06
US20160075731A1 (en) 2016-03-17
EP2968385A1 (en) 2016-01-20
KR20150131181A (ko) 2015-11-24
US11124536B2 (en) 2021-09-21
PT2968385T (pt) 2018-10-09
JP2016513668A (ja) 2016-05-16
EA034135B1 (ru) 2020-01-09
PL2968385T3 (pl) 2019-05-31
ZA201507045B (en) 2020-01-29
SI2968385T1 (sl) 2018-10-30

Similar Documents

Publication Publication Date Title
EA034135B9 (ru) Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
WO2015108490A3 (en) Heteroaryl alkyne derivatives and uses thereof
PH12015500963A1 (en) Tricyclic fused thiophene derivatives as jak inhibitors
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2016002238A (es) Alcoholes de alquilino y metodos de uso.
TR201901886T4 (tr) DNA-PK inhibitörleri.
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
MX2016008110A (es) Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
MX364486B (es) Derivados de piridazinona-amidas.
NZ708727A (en) Conjugate compounds
PH12019500196A1 (en) Compounds and compositions and uses thereof
WO2014151456A3 (en) Treatment of inflammatory diseases
IN2014CN03043A (ru)
MX2020006614A (es) Derivados de cromenopiridina como inhibidores de fosfatidilinositol fosfato cinasa,.
TN2015000120A1 (en) Oxazolidin-2-one-pyrimidine derivatives
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2017003016A (es) Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas.

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent